Purpose: Curcumin as a potent anti-inflammatory and cancer-prevention molecule was labeled with n.c.a 177Lu. The combi-nation of 177Lu as a theranostic agent and curcumin as an anti-cancer can be considered for nuclear medicine. Methods: First, n.c.a 177Lu (specific activity = 48 Ci/mg) was prepared using the extraction chromatography method. Then,semi-empirical quantum chemical calculations were applied to get a deeper insight into the complexation reaction between Lu+3 and curcumin ligand. UV-Vis spectrophotometry was used for the determination of the metal-to-curcumin ratio. Sub-sequently, a mixture of (111–333 MBq) n.c.a 177Lu, 50 µL curcumin solution in ethanol, and 450 µL acetate buffer at pH = 5was incubated for 1  h at 95 ºC. The Lu-curcumin complex chemical structure was characterized using IR spectroscopy.Finally, the prepared complex was analyzed by different quality control tests. Results: Complexometry using UV-Vis studies showed a 1:2 ratio for Lutetium: curcumin complex which is in agreement with theoretical calculations. The IR-spectra analysis also confirmed the complex formation. The radiochemical purity of n.c.a 177Lu -curcumin was more than 95% as determined by radio-TLC. The stability of up to 48 h was observed for theprepared complex in serum. The partition coefficient was calculated for the compound (logP = -0.31). Evaluating biodistri-bution in tumoral mice exhibited high tumor uptake (%ID/gtissue = 2.03). Conclusion The promising results showed that n.c.a 177Lu-curcumin can be considered as a possible radiopharmaceutical agent for therapeutic applications.

Purpose: Curcumin as a potent anti-inflammatory and cancer-prevention molecule was labeled with n.c.a 177Lu. The combi-nation of 177Lu as a theranostic agent and curcumin as an anti-cancer can be considered for nuclear medicine. Methods: First, n.c.a 177Lu (specific activity = 48 Ci/mg) was prepared using the extraction chromatography method. Then,semi-empirical quantum chemical calculations were applied to get a deeper insight into the complexation reaction between Lu+3 and curcumin ligand. UV-Vis spectrophotometry was used for the determination of the metal-to-curcumin ratio. Sub-sequently, a mixture of (111–333 MBq) n.c.a 177Lu, 50 µL curcumin solution in ethanol, and 450 µL acetate buffer at pH = 5was incubated for 1  h at 95 ºC. The Lu-curcumin complex chemical structure was characterized using IR spectroscopy.Finally, the prepared complex was analyzed by different quality control tests. Results: Complexometry using UV-Vis studies showed a 1:2 ratio for Lutetium: curcumin complex which is in agreement with theoretical calculations. The IR-spectra analysis also confirmed the complex formation. The radiochemical purity of n.c.a 177Lu -curcumin was more than 95% as determined by radio-TLC. The stability of up to 48 h was observed for theprepared complex in serum. The partition coefficient was calculated for the compound (logP = -0.31). Evaluating biodistri-bution in tumoral mice exhibited high tumor uptake (%ID/gtissue = 2.03). Conclusion The promising results showed that n.c.a 177Lu-curcumin can be considered as a possible radiopharmaceutical agent for therapeutic applications.

Purpose: Curcumin as a potent anti-inflammatory and cancer-prevention molecule was labeled with n.c.a 177Lu. The combi-nation of 177Lu as a theranostic agent and curcumin as an anti-cancer can be considered for nuclear medicine. Methods: First, n.c.a 177Lu (specific activity = 48 Ci/mg) was prepared using the extraction chromatography method. Then,semi-empirical quantum chemical calculations were applied to get a deeper insight into the complexation reaction between Lu+3 and curcumin ligand. UV-Vis spectrophotometry was used for the determination of the metal-to-curcumin ratio. Sub-sequently, a mixture of (111–333 MBq) n.c.a 177Lu, 50 µL curcumin solution in ethanol, and 450 µL acetate buffer at pH = 5was incubated for 1  h at 95 ºC. The Lu-curcumin complex chemical structure was characterized using IR spectroscopy.Finally, the prepared complex was analyzed by different quality control tests. Results: Complexometry using UV-Vis studies showed a 1:2 ratio for Lutetium: curcumin complex which is in agreement with theoretical calculations. The IR-spectra analysis also confirmed the complex formation. The radiochemical purity of n.c.a 177Lu -curcumin was more than 95% as determined by radio-TLC. The stability of up to 48 h was observed for theprepared complex in serum. The partition coefficient was calculated for the compound (logP = -0.31). Evaluating biodistri-bution in tumoral mice exhibited high tumor uptake (%ID/gtissue = 2.03). Conclusion The promising results showed that n.c.a 177Lu-curcumin can be considered as a possible radiopharmaceutical agent for therapeutic applications.

Purpose: Curcumin as a potent anti-inflammatory and cancer-prevention molecule was labeled with n.c.a 177Lu. The combi-nation of 177Lu as a theranostic agent and curcumin as an anti-cancer can be considered for nuclear medicine. Methods: First, n.c.a 177Lu (specific activity = 48 Ci/mg) was prepared using the extraction chromatography method. Then,semi-empirical quantum chemical calculations were applied to get a deeper insight into the complexation reaction between Lu+3 and curcumin ligand. UV-Vis spectrophotometry was used for the determination of the metal-to-curcumin ratio. Sub-sequently, a mixture of (111–333 MBq) n.c.a 177Lu, 50 µL curcumin solution in ethanol, and 450 µL acetate buffer at pH = 5was incubated for 1  h at 95 ºC. The Lu-curcumin complex chemical structure was characterized using IR spectroscopy.Finally, the prepared complex was analyzed by different quality control tests. Results: Complexometry using UV-Vis studies showed a 1:2 ratio for Lutetium: curcumin complex which is in agreement with theoretical calculations. The IR-spectra analysis also confirmed the complex formation. The radiochemical purity of n.c.a 177Lu -curcumin was more than 95% as determined by radio-TLC. The stability of up to 48 h was observed for theprepared complex in serum. The partition coefficient was calculated for the compound (logP = -0.31). Evaluating biodistri-bution in tumoral mice exhibited high tumor uptake (%ID/gtissue = 2.03). Conclusion The promising results showed that n.c.a 177Lu-curcumin can be considered as a possible radiopharmaceutical agent for therapeutic applications.

Purpose: Curcumin as a potent anti-inflammatory and cancer-prevention molecule was labeled with n.c.a 177Lu. The combi-nation of 177Lu as a theranostic agent and curcumin as an anti-cancer can be considered for nuclear medicine. Methods: First, n.c.a 177Lu (specific activity = 48 Ci/mg) was prepared using the extraction chromatography method. Then,semi-empirical quantum chemical calculations were applied to get a deeper insight into the complexation reaction between Lu+3 and curcumin ligand. UV-Vis spectrophotometry was used for the determination of the metal-to-curcumin ratio. Sub-sequently, a mixture of (111–333 MBq) n.c.a 177Lu, 50 µL curcumin solution in ethanol, and 450 µL acetate buffer at pH = 5was incubated for 1  h at 95 ºC. The Lu-curcumin complex chemical structure was characterized using IR spectroscopy.Finally, the prepared complex was analyzed by different quality control tests. Results: Complexometry using UV-Vis studies showed a 1:2 ratio for Lutetium: curcumin complex which is in agreement with theoretical calculations. The IR-spectra analysis also confirmed the complex formation. The radiochemical purity of n.c.a 177Lu -curcumin was more than 95% as determined by radio-TLC. The stability of up to 48 h was observed for theprepared complex in serum. The partition coefficient was calculated for the compound (logP = -0.31). Evaluating biodistri-bution in tumoral mice exhibited high tumor uptake (%ID/gtissue = 2.03). Conclusion The promising results showed that n.c.a 177Lu-curcumin can be considered as a possible radiopharmaceutical agent for therapeutic applications.

BACKGROUND: According to the fact that women account for the highest rate of victims of mental health loss during disasters, prioritization of their requirements is of remarkable significance. Therefore, the present study was carried out with the aim to prioritize factors related to women's mental health during an earthquake. METHODS: This study was conducted using the Delphi method in 2017. Participants consisted of experts including psychologists, counselors and psychiatrists, social medicine specialists, and psychiatric-mental health nurses with experience in service and disaster awareness, especially earthquake. They were selected using purposive and snowball sampling methods. The Delphi method was used in 2 rounds with 21 components and the final attendance of 19 participants and the collective agreement of 75%. RESULTS: Of the 21 factors related to women's mental health during the earthquake, the following components were, respectively, preferred by the participants: psychological well-being training, group relationships and support of women in emergency situations, fair treatment in the provision of rights and services to women, crisis awareness and management of behavior and difficult conditions, and social security during disasters with the total mean standard deviation (SD) of 13.4 (2.4), 13.0 (2.4), 12.7 (2.5), 12.5 (2.4), and 12.3 (2.2), respectively. CONCLUSION Training in the field of psychology and disasters, and social and cultural factors were prioritized among factors related to women's mental health during an earthquake. Therefore, the results of this study can be applied by the planners and executives of mental health, women and disasters, and the women's community itself.

OBJECTIVE: To assess the efficacy of a curcumin supplementation on cognitive abilities in women suffering from premenstrual syndrome (PMS) and dysmenorrhea. METHODS: A randomized, triple-blind, placebo-controlled trial was conducted from December 2019 to March 2020. A total of 124 women who had both PMS and dysmenorrhea were enrolled, and were equally and randomly assigned to the curcumin group or placebo group, 62 cases in each. Each subject received either a capsule containing 500 mg of curcuminoid, or a placebo daily, for 10 days (7 days before and until 3 days after the onset of menstrual bleeding) over 3 menstrual cycles. The cognitive abilities questionnaire was used to measures cognitive functions in 7 specific areas. Adverse reactions were monitored during and after the trial in both groups. RESULTS: Administration of curcumin was associated with a significant increase in memory score (P=0.002), inhibitory control and selective attention (P=0.020), and total cognitive ability task (P=0.024). In addition, significant increments were found in scores of memory (3.5±3.1 vs. 0.4±3.8 in the curcumin and placebo groups, respectively; P=0.035), inhibitory control and selective attention (3.0±3.7 vs. 0.4±3.7; P=0.027) and total cognitive abilities (8.3±12.3 vs. 2.2±12.4; P=0.025) in the curcumin group versus placebo groups. Curcumin was safe and well-tolerable in current clinical trial. CONCLUSION Curcumin has a beneficial efficacy on cognitive function scores in women with PMS and dysmenorrhea, with improvements in memory, inhibitory control and selective attention. (Registration No. IRCT20191112045424N1, available at: https://www.irct.ir ).
Humans ; Female ; Curcumin/therapeutic use* ; Dysmenorrhea/drug therapy* ; Premenstrual Syndrome/psychology* ; Cognition ; Double-Blind Method